improving nature s own defense mechanisms Company presentation

Transcription

1 improving nature s own defense mechanisms Company presentation August 2013

2 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Aims to develop novel therapeutics for areas of high unmet needs: Infectious diseases Oncology Oslo

3 Lytix Biopharma is a clinical-stage company 3

4 4 Strong IPR State of the art patent strategy 12 patent families 21 patents granted 65 patents pending Broad patent protection covering Technology platform Method of use Composition of matter from Additional features Patent base allows for the development of multiple product candidates Patents applied for major markets

5 5 Highly competent management team Unni Hjelmaas CEO Extensive senior management experience from Roche, former General Manager for Roche Norway Several positions in sales and marketing, substantial experience is in oncology, life cycle management, international strategy and marketing experience from Roche HQ in Basel Former Chairman and current member of the Board of the Norwegian Pharma Industry Association Cand.pharm, Pharmacy from the University of Oslo Gunnar Sælid Senior Advisor Previous CEO of Lytix Biopharma, extensive senior management experience from the pharmaceutical industry (Nycomed, GE Health and Novartis), life science research and business facilitation (The National Hospital, Oslo Research Park) and seed finance (Start Foundation) Previously life science board positions (The Biotechnology Centre of Oslo, The Norwegian Research Council) MSc in biochemistry Øystein Rekdal, PhD Co-founder and director, Oncology Research CEO of Lytix Biopharma from establishment in 2003 Extensive research background in peptide chemistry, biochemistry and tumour biology PhD from the University of Tromsø, Professor in the Medical Biochemistry Department in the Faculty of Medicine at the University of Tromsø Wenche Marie Olsen, DrPhilos COO Broad experience within research, development and management of new drug products in pharmaceutical and biotech industry Former CEO of Lauras, various positions in Nycomed/GE Healthcare PhD in medical biochemistry from the National Hospital, University of Oslo Anders Fugelli, PhD Director, Business Development Strong track record in management roles in several Norwegian companies in the Life Sciences sector Formerly GlaxoSmithKline PhD in pharmacology/biochemistry from the University of London John S. Svendsen, PhD Co-founder and Director, Discovery Research Extensive research experience in medical biochemistry, synthetic organic chemistry and medicinal chemistry, specialising in antibacterial peptides Visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at MIT PhD from the University of Tromsø, Professor of organic chemistry at the University of Tromsø

6 6 Experienced Board of Directors Knut Eidissen Chairman Owner and managing director of the consulting and investment company Picasso Extensive experience as a board member from both private and as public limited companies Strong track record in creating shareholder value, e.g. as chairman of the oil-and oil service company, Altinex Siri Fürst Thorough experience in the pharmaceutical sector, e.g., from Nycomed, where she held the position as director administration, strategy and business development and as Vice President Investor Relations Currently partner in Considium Consulting Group and a board member with SNN Invest Karl-Johan Jakola - Vice Chairman Managing partner of NorInnova Forvaltning Substantial experience from business development and financing of start-up companies Alf Lindberg Professor in clinical bacteriology, has been Chief Scientific Officer and Head of R&D at Wyeth Lederle Vaccines Former Executive VP of R&D at Pasteur Merieux Connaught, member of the Nobel Assembly and member of the Board of Directors of the Nobel Foundation Serves on several Scientific Advisory Boards. Currently he is the CEO of Nobel Web Håvard Selby Ebbestad CEO of Fürst Medisinsk Laboratorium, one of the leading medical laboratories in Europe Former Managing Director of Zeneca, Pharmacia and Pfizer in Norway and Chairman of the board of LMI (The Association of the Pharmaceutical Industry in Norway) Steinar Høeg Director External Affairs Europe in AstraZeneca since 2010 Former Marketing Company President for Astra/AstraZeneca in Norway, Sweden and in the Nordics, member of the European Management Team, member of the Norwegian Trade Association and Chair of the Swedish trade association for research based pharmaceutical companies John Sigurd Svendsen (see management CVc)

7 7 Lytix Biopharma scientific background T=5 minutes LTX-109 (infection) LTX-315 (cancer) Lactoferrin Lactoferricin The lactoferrin protein is found in milk and is known to have direct anti-microbial activity and cancer immune modulatory effects Structure-activity-relationship studies have resulted in the design of two optimal molecules originating from the Company s technology platform; the anti-infective drug LTX-109 and the cancer immune therapeutic drug LTX-315

8 8 Highly efficient peptides Ultra rapid membrane disruption Time: 0 min 5 min 10 min 20 min Host defence peptides form the cornerstone of the body s protection against a broad spectrum of harmful micro-organisms Some host defence peptides kill micro-organisms by direct disruption of the cell membrane (lysis). Such lytic peptides represent a novel class of drugs More recent research has shown that some host defence peptides have powerful anti-cancer effects. These peptides induce release of danger signals and tumor associated antigens (TAAs) from the tumor leading to protective immune responses

9 LTX-315 induces tumor regression and protective immunity 9 Kills cancer cells, including MDR phenotypes Knocks out tolarized tumor-infiltrating lymphocytes (TILs) Signals danger and causes inflammation Releases tumor-associated antigens (TAAs) Attracts new TILs Immune-active tumor micro-environment favors response to check-point blockade inhibitors. LTX-315 may therefore represent an ideal synergistic combination partner in future cancer treatment

10 10 LTX-109 is a well-documented drug candidate Fast acting, bactericidal antimicrobial drug Broad spectrum of activity Low propensity for resistance development Effective against multi-drug resistant bacteria Effective against biofilms

11